RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pharming Group Stock

Pharming Group ROA 2025

Pharming Group ROA

-0.03

Ticker

PHARM.AS

ISIN

NL0010391025

WKN

A1H65A

In 2025, Pharming Group's return on assets (ROA) was -0.03, a 29.9% increase from the -0.02 ROA in the previous year.

Pharming Group Aktienanalyse

What does Pharming Group do?

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Pharming Group's Return on Assets (ROA)

Pharming Group's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Pharming Group's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Pharming Group's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Pharming Group’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Pharming Group stock

What is the Return on Assets (ROA) of Pharming Group this year?

The Return on Assets (ROA) of Pharming Group is -0.03 undefined this year.

What was the ROA of Pharming Group compared to the previous year?

The ROA of Pharming Group has increased by 29.9% compared to the previous year.

What consequences do high ROA have for investors of Pharming Group?

A high ROA is advantageous for investors of Pharming Group, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Pharming Group?

A low ROA can be unfavorable for investors of Pharming Group as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Pharming Group affect the company?

An increase in ROA of Pharming Group can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Pharming Group impact the company?

A reduction in the ROA of Pharming Group can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Pharming Group?

Some factors that can influence the ROA of Pharming Group include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Pharming Group important for investors?

The ROA of Pharming Group is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Pharming Group take to improve ROA?

To improve ROA, Pharming Group can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Pharming Group pay?

Over the past 12 months, Pharming Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharming Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Pharming Group?

The current dividend yield of Pharming Group is .

When does Pharming Group pay dividends?

Pharming Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharming Group?

Pharming Group paid dividends every year for the past 0 years.

What is the dividend of Pharming Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharming Group located?

Pharming Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharming Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharming Group from 7/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/29/2025.

When did Pharming Group pay the last dividend?

The last dividend was paid out on 7/29/2025.

What was the dividend of Pharming Group in the year 2024?

In the year 2024, Pharming Group distributed 0 USD as dividends.

In which currency does Pharming Group pay out the dividend?

The dividends of Pharming Group are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pharming Group stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pharming Group

Our stock analysis for Pharming Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.